Journal article icon

Journal article

Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.

Abstract:

Many anticancer therapies, including ionizing radiation (IR), cause cytotoxicity through generation of DNA double-strand breaks (DSB). Delivery of therapeutic radionuclides to DNA DSB sites can amplify this DNA damage, for additional therapeutic gain. Herein, we report on two radiopharmaceuticals, radiolabeled with the Auger electron emitter (111)In, with dual specificity for both the intranuclear, DNA damage repair signaling protein γH2AX and the EGF receptor (EGFR). The EGFR ligand EGF was ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Role:
Author
Cancer Research UK More from this funder
CR-UK/EPSRC Cancer Imaging Centre More from this funder
Oxford Experimental Cancer Medicine Centre More from this funder
Publisher:
American Association for Cancer Research Publisher's website
Journal:
Molecular cancer therapeutics Journal website
Volume:
12
Issue:
11
Pages:
2472-2482
Publication date:
2013-11-05
DOI:
EISSN:
1538-8514
ISSN:
1535-7163
URN:
uuid:cdc2baa5-c9a3-443c-a446-c5b94a38aed7
Source identifiers:
436127
Local pid:
pubs:436127

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP